Advertisement

What Are Immunosuppressive Medications? How Do They Work? What Are Their Side Effects?

  • Peter Chung-Wen Chang
  • Donald E. Hricik
Chapter

Abstract

Effective suppression of the transplant recipient’s immune system has improved short-term outcomes in renal transplantation. The immunologic basis for graft rejection is described in Chapter 3. Although there are infrequent reports of patients requiring little or no immunosuppressive medications, most patients require life-long immunosuppression.

Keywords

Acute Rejection Induction Therapy mTOR Inhibitor Mycophenolic Acid Azole Antifungal Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004;15:3256–3262.CrossRefPubMedGoogle Scholar
  2. 2.
    Stegall MD, Gloor J, Winters JL et al. A comparison of plasmapheresis versus high-dose IVIg desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006;6:346–351.CrossRefPubMedGoogle Scholar
  3. 3.
    Gloor JM, DeGoey SR, Pineda AA et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003;3:1017–1022.CrossRefPubMedGoogle Scholar
  4. 4.
    Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center’s perspective. Pediatr Transplant 2004;8:535–542.CrossRefPubMedGoogle Scholar
  5. 5.
    Tyden G, Kumlein G, Genberg H et al. ABO incompatible kidney transplantations without splenectomy using antigen specific immunoadsorption and rituximab. Am J Transplant 2005;5:145–148.CrossRefPubMedGoogle Scholar
  6. 6.
    Schwartz J, Stegall MD, Kremers WK et al. Complications, resource utilization and cost of ABO-incompatible living donor kidney transplantation. Transplantation 2006;82:155–163.CrossRefPubMedGoogle Scholar
  7. 7.
    Szczech LA, Berlin JA, Aradhye S et al. Effect of antilymphocyte induction on renal allograft survival: a meta-analysis. J Am Soc Nephrol 1997;8:1771–1777.PubMedGoogle Scholar
  8. 8.
    Belitsky P, MacDonald AS, Lawen J et al. Use of rabbit anti-thymocyte globulin for induction immunosuppression in high-risk kidney transplant recipients. Transplant Proc 1997;29(Suppl 7A):16.CrossRefGoogle Scholar
  9. 9.
    Brennan DC, Daller JA, Lake KD et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Eng J Med 2006;355:1967–1977.CrossRefGoogle Scholar
  10. 10.
    Bloom DD, Hu H, Fechner JH et al. T-lymphocyte alloresponses of campath 1-H treated kidney transplant patients. Transplantation 2006;81:81–87.CrossRefPubMedGoogle Scholar
  11. 11.
    Shapiro R, Basu A, Tan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion either thymoglobulin or campath. J Am Coll Surg 2005;200:505–515.CrossRefPubMedGoogle Scholar
  12. 12.
    Watson CJ, Bradley JA, Friend PJ et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation – efficacy and safety at five years. Am J Transplant 2005;5:1347–1353.CrossRefPubMedGoogle Scholar
  13. 13.
    Barth RN, Janus CA, Lilesand CA et al. Outcomes at 3 years of a prospective pilot study of campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006;19:885–892.CrossRefPubMedGoogle Scholar
  14. 14.
    Flechner SM, Friend PJ, Brockmann J et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005;5:3009–3014.CrossRefPubMedGoogle Scholar
  15. 15.
    Norman DJ, Kahana L, Stuart FP et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993;55:44–50.Google Scholar
  16. 16.
    Nashan B, Moore R, Amlot P et al. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997;1:1193.CrossRefGoogle Scholar
  17. 17.
    Vincenti F, Kirkman R, Light S et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998;338:161–165.CrossRefPubMedGoogle Scholar
  18. 18.
    Ahsan N, Holman MJ, Jarowenko MV et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002;2:568–573.CrossRefPubMedGoogle Scholar
  19. 19.
    Ter Meulen CG. Two doses of Daclizumab are sufficient for prolonged interleukin-2R chain blockade. Transplantation 2001;72:1709–1710.CrossRefPubMedGoogle Scholar
  20. 20.
    Hollenberg SM, Evans RM. Multiple and cooperative trans-activation domains of the human glucocorticoid receptor. Cell 1988;55:899–906.CrossRefPubMedGoogle Scholar
  21. 21.
    Augustine JJ, Hricik DE. Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol 2006;1:1080–1089.CrossRefPubMedGoogle Scholar
  22. 22.
    First MR. Improving long-term renal transplant outcomes with tacrolimus: speculation vs evidence. Nephrol Dial Transplant 2004;19(Suppl 6):17–22.CrossRefGoogle Scholar
  23. 23.
    Dunn CJ, Wagstaff AJ, Perry CM et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical Efficacy and tolerability of a microemulsion-based formulation (neoral) in organ transplantation. Drugs 2001;61:1957–2016.CrossRefPubMedGoogle Scholar
  24. 24.
    Scott LJ, McKeage K, Keam SJ et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003;63:1247–1297.CrossRefPubMedGoogle Scholar
  25. 25.
    Waiser J, Slowinski T, Brinker-Paschke A et al. Impact of the variability of cyclosporin A trough levels on long-term allograft function. Nephrol Dial Transplant 2002;17:1310–1317.CrossRefPubMedGoogle Scholar
  26. 26.
    Fung JJ. Tacrolimus and transplantation: a decade in review. Transplantation 2004;77(9 Suppl):S41–S43.CrossRefPubMedGoogle Scholar
  27. 27.
    Danovitch GM. Immunosuppressive medications and protocols for kidney transplantation. In: Danovitch GM, (ed.), Handbook of Kidney Transplantation. Philadelphia, PA, Lippincott Williams & Wilkins, 2005, pp. 72–134.Google Scholar
  28. 28.
    Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002;2:807–818.CrossRefPubMedGoogle Scholar
  29. 29.
    Jurewicz WA. Tacrolimus versus ciclosporin immunosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 2003;18(Suppl 1):7–11.CrossRefGoogle Scholar
  30. 30.
    Claesson K, Mayer AD, Squifflet JP et al. Lipoprotein patterns in renal transplant patients: a comparison between FK506 and cyclosporine A patients. Transplant Proc 1998;30:1292–1294.CrossRefPubMedGoogle Scholar
  31. 31.
    Jensik SC. Tacrolimus (FK506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. Transplant Proc 1998;30:1216–1218.CrossRefPubMedGoogle Scholar
  32. 32.
    Heisel O, Heisel R, Balshaw R et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4:583–595.CrossRefPubMedGoogle Scholar
  33. 33.
    Tanabe K. Calcineurin inhibitors in renal transplantation. Drugs 2003;63:1535–1548.CrossRefPubMedGoogle Scholar
  34. 34.
    Siegel CT. Maintenance immunosuppression. In: Hricik DE, (ed.), Kidney Transplantation. Chicago, IL, Remedica, 2007, pp. 55–75.Google Scholar
  35. 35.
    Braun WE. Renal transplantation: basic concepts and evolution of therapy. J Clin Apher 2003;18:141–152.CrossRefPubMedGoogle Scholar
  36. 36.
    Chan GLC, Canafax DM, Johnson CA. The therapeutic use of azathioprine in renal transplantation. Parmacotherapy 1987;7:165–177.Google Scholar
  37. 37.
    Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003;75:1341–1346.CrossRefPubMedGoogle Scholar
  38. 38.
    Allison AC, Eugui EM. Mechanism of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005;80(2 Suppl):S181–S190.CrossRefPubMedGoogle Scholar
  39. 39.
    Pelletier RP, Akin B, Henry ML et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003;17:200–205.CrossRefPubMedGoogle Scholar
  40. 40.
    Sollinger H. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. Transplant Proc 2004;36(Suppl):S517–S520.CrossRefGoogle Scholar
  41. 41.
    Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008;22:1–15.CrossRefPubMedGoogle Scholar
  42. 42.
    Johnson RW. How should sirolimus be used in clinical practice? Transplant Proc 2003;35(3 Suppl):S79–S83.CrossRefGoogle Scholar
  43. 43.
    Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005;28:153–181.CrossRefPubMedGoogle Scholar
  44. 44.
    Chueh SC, Kahan BD. Clinical application of sirolimus in renal transplantation: an update. Transpl Int 2005;18:261–277.CrossRefPubMedGoogle Scholar
  45. 45.
    Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007;67:369–391.CrossRefPubMedGoogle Scholar
  46. 46.
    Valente JF, Hricik D, Weigel K et al. Comparison of sirolimus vs mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003;3:1128–1134.CrossRefPubMedGoogle Scholar
  47. 47.
    Webster AC, Lee VW, Chapman JR et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006;81:1234–1248.CrossRefPubMedGoogle Scholar
  48. 48.
    Romagnoli J, Citterio F, Nanni G et al. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 2006;38:1034–1036.CrossRefPubMedGoogle Scholar
  49. 49.
    Kauffman HM, Cherikh WS, Cheng Y et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883–889.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag US 2010

Authors and Affiliations

  1. 1.Division of Nephrology and Hypertension, Department of MedicineUniversity Hospitals Case Medical CenterClevelandUSA

Personalised recommendations